Multiple sclerosis Home - About Antigenics - Disease Areas - Multiple sclerosis What is multiple sclerosis?
Should I have disease-modifying therapy for multiple sclerosis? - Quest Diagnostics Patient Health Library Should I have disease-modifying therapy for multiple sclerosis?interferon beta or glatiramer acetate as soon as MS is diagnosed.Interferon beta or glatiramer acetate can reduce the frequency and...
Interferon beta for multiple sclerosis - [Medication] - Quest Diagnostics Patient Health Library Interferon beta for multiple sclerosis Examples Brand Name Chemical Name Avonex, Rebif, Betaseron interferon beta How It Works The interferon beta medications resemble the natural interferon the body produces during a response by the immune system to disease.
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
BioPortfolio Limited Multiple Sclerosis 5.1 Introduction 5.2 The Different Categories of MS 5.2.1 Benign MS 5.2.2 Relapse-remitting MS 5.2.3 Primary progressive MS 5.2.4 Secondary progressive 5.2.5 Progressive relapsing MS 5.3 Symptoms and Differential Diagnosis 5.3.1 Primary symptoms 5.3.2 Secondary symptoms 5.3.3 Tertiary symptoms Table 5.1 Breakdown of MS Symptoms 5.3.4 Diagnosis 5.4 The Risk factors...
Avonex Is Not an Orphan Any More Serono's (NYSE: SRA) Rebif and Biogen's (NASDAQ: BGEN) Avonex are similar drugs; both are recombinant forms of interferon beta -1a that treat relapsing-remitting multiple sclerosis (RRMS).Rebif because it generated better treatment results than Avonex in a head-to-head trial, at least superficially.
Rebif Beats Avonex In Head-To-Head Trial - - - - BioNews BioWeb Companies Products BioReports - - - - - Rebif Beats Avonex In Head-To-Head Trial Tuesday, Serono (NYSE: SRA) released 48-week data from its head-to-head trial of Rebif against Biogen's (NASDAQ: BGEN) Avonex in the treatment of relapsing-remitting multiple sclerosis (RRMS).interferon beta -1a ...
Avonex Loses Again Betaseron is an interferon beta -1b formulation while Avonex and Rebif are interferon beta -1a formulations.interferon beta -1a product with the dosing characteristics of Rebif. Beta -1b recipients were 24% less likely to experience a relapse than beta -1a ...
Campath for Multiple Sclerosis - - - - BioNews BioWeb Companies Products BioReports - - - - - - Biotech Tracker News - Campath for Multiple Sclerosis April 03, 2003.Rebif (interferon beta -1a), with primary attention to the prevention of “sustained accumulative disability” in...
BioPortfolio Limited 39 Chapter 2 Erythropoietins 44 Summary 44 Class overview 44 Mechanism of action 46 Global sales 46 Analysis of leading products 47 Procrit/Eprex (epoetin alpha) 47 Epogen (epoetin alpha) and Aranesp (darbepoetin alpha) 50 NeoRecormon/Epogin (epoetin beta) 52 Late stage R&D activity 53 Hemolink (hemoglobin raffimer) 54 Chapter 3 Interferons 56 Summary 56 Class overview 57...
Approved Products_2004.xls Number A pproval Date Trade Name Generic/ Chemical name Indication Company 1 Oct- 82 Humulin Human Insulin Type I Diabetes Lilly / Genentech 2 Oct- 85 Protro pin Human Growth Hormone Hypoptuitary dwarfism Genentech 3 Jun- 86 Intron A Interferon Al pha 2B Hairy Cell Leukemia Schering Plough / Biogen 4 Jun- 86 OKT- 3 Anti CD3 Mab Acute Trans plant Rejection JNJ / OrthoBiotech 5...
author: Reijer
http://www.amarbio.com/AJVR.pdf page 10
Database R R - investigational drugs, therapies and- vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
Database I See hFAT (3321) IGN101 Vaccine (3250) IGN201 Vaccine (3252) IGN301 Vaccine (3249) IGN311 Antibody (HuABL346, Anti-Lewis Y Antibody) (2963) IGN402 Vaccine (3253) IL-1 (Interleukin-1) Receptor Type II (1943) IL-1 Trap (Interleukin-1 Trap) (2254) IL-12 Cytokine Combination (1594) IL-12 (Interleukin-12) Interferon -alfa Combination Gene Medicine (1593) IL-13R alpha2 (Interleukin-13...
Therapeutic Biological Approvals - Chiron Corporation 4560 Horton Street Emeryville, CA 94608 License 1106 12/16/1997 AVONEX Interferon beta -1a Revised Package Insert: Updated information regarding serum neutralizing antibodies 103628 / 5008 Biogen, Inc 14 Cambridge Center Cambridge, MA 02142 License 1204 11/12/2002 Betaseron Interferon beta -1b Revised Package Insert: Revised the...
Office of Drug Safety: Patient Labeling and Risk Communitation Food and Drug Administration • Center for Drug Evaluation and Research Office of Drug Safety Search Patient Labeling and Risk Communication FDA-Approved Patient Labeling Patient Package Inserts.- For some prescription medicines, FDA approves special patient materials to instruct patients about the safe use of the product
author: PhillipsJ
Newsroom Home - Newsroom Current News Archived News Newsroom July 23, 2002 ECRIa€™s Evidence-Based Analysis Verifies the Effectiveness of Interferon Beta -1a and -1b Treatments for Relapsing-Remitting Multiple Sclerosis PLYMOUTH MEETING, PA—Multiple sclerosis (MS) affects more than 300,000 people in the United States and more than one million people worldwide...
Pharmaceutical Research and Manufacturers of America 4 combination regimen - Pivanex Pivanex / cell differentiating agent Non-Small-Cell Lung Cancer Titan Pharmaceuticals South San Francisco, CA Phase II - Prothecan none / PED-camptothecin Gastric (stomach) cancer Non-Small-Cell Lung Cancer Pancreatic Cancer Small-Cell Lung Cancer Enzon Bridgewater, NJ Phase II - pyrazine diaohydroxide none / pyrazine diaohydroxide Lung Cancer Non...
Pharmaceutical Research and Manufacturers of America - Peripheral Demyelinating Disorder Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes Rebif Rebif / human interferon beta -1a Central Demyelinating Disorder Chronic Hepatitis C...
Pharmaceutical Research and Manufacturers of America - Chronic Hepatitis C Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes Albuferon Albuferon / none Chronic Hepatitis C Human Genome Sciences Rockville, MD Phase I - Alferon N Injection¨ Alferon N Injection...
Pharmaceutical Research and Manufacturers of America - Central Demyelinating Disorder Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes Rebif Rebif / human interferon beta -1a Central Demyelinating Disorder Chronic Hepatitis C Crohn's...
BIO 2003: Teri Garr, Actor and Multiple Sclerosis Activist Home Page Schedule of Events Program Content Sponsor Information Exhibit Information Business Forum International Delegations Media Information About BIO - Other BIO Events 2004 & Beyond BIO 2002 Teri Garr, Actor and Multiple Sclerosis Activist Wednesday, June 25, Plenary Luncheon Video (Real) Teri Garr, one of Hollywood's most versatile, energetic and well-recognized actresses, has...
CBER Approval Letter, Interferon beta-1a, Rebif, Serono, Inc FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Product Approval Information - DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration 1401 Rockville Pike Rockville, MD 20852-1448 May 2, 2003 Our STN: BL 103780/5010 Pamela Williamson Joyce Serono, Incorporated One Technology Place Rockland, MA 02370...
CBER - Interferon beta-1a, Rebif, Serono, Inc Interferon beta -1a is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disabilityRebif, and will be marketed in 0.5 mL pre-filled, single-use syringes...
News Along the Pike, November-October 2002 Food and Drug Administration • Center for Drug Evaluation and Research Center for Drug Evaluation and Research Search - CDER News Along the Pike December 31, 2002 Volume 8, Issue 5 Center for Drug Evaluation and Research PDF version for printouts Index 20,000 pharmacies use Center's public education ads By Cindi Fitzpatrick CBER official highlights biologics review science By...
author: PDA
